



## Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference

February 6, 2023

PALO ALTO, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vincerx's management team will present the company's corporate overview and participate in one-on-one investor meetings at the SVB Securities Global Biopharma Conference, to be held virtually from February 14-16, 2023.

### SVB Securities Global Biopharma Conference Presentation Details

Date: Thursday, February 16, 2023

Time: 1:40 p.m. ET

Webcast: <https://wsw.com/webcast/svb8/vinc/1621296>

An archived webcast will be accessible in the [Investors](#) section of the Company's website for approximately 90 days following the event.

### About Vincerx Pharma, Inc.

Vincerx Pharma, Inc. (Vincerx) is a clinical-stage biopharmaceutical company committed to developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. Vincerx has assembled a seasoned management team with a proven track record of successful oncology drug development, approvals, and value creation. The company's diverse pipeline consists of enitociclib, currently in Phase 1, and a proprietary modular bioconjugation platform, which includes a small molecule drug-conjugate, VIP236, in Phase 1, and preclinical next-generation antibody drug conjugates, VIP943 and VIP924.

Vincerx Pharma is based in Palo Alto, Calif., and has a research facility in Monheim, Germany. For more information, please visit [www.vincerx.com](http://www.vincerx.com).

### Contacts

Bruce Mackle

LifeSci Advisors, LLC

646-889-1200

[bmackle@lifesciadvisors.com](mailto:bmackle@lifesciadvisors.com)



Source: Vincerx Pharma, Inc.